Telum Therapeutics
Telum Therapeutics Raises €18M Series A for Protein-Based Antimicrobials
Telum Therapeutics announced €18M in Series A financing on July 1, 2026. Telum Therapeutics raised an €18 million Series A led by AMR Action Fund to advance its lead antimicrobial program through Phase 1 clinical development.
Round details
The financing includes backing from AMR Action Fund, Inveready, Invivo Partners, CDTI (SICC Innvierte), Clave Capital, Sodena. The company did not publish a valuation with the announcement.
- Round: Series A
- Capital announced: €18M
- Headquarters: Spain
How the company plans to use the capital
Telum will advance its lead candidate, developed for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii, through Phase 1 clinical development. The company also said the financing will help it advance its broader pipeline addressing Gram-negative and Gram-positive pathogens.
Why this matters for GTM teams
Existing investors Invivo Partners, CDTI (SICC Innvierte), Clave Capital and Sodena continued their support in the round, which also added AMR Action Fund and Inveready as new investors.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Telum Therapeutics Series A announcement.
Company Info
Investors (6)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started